ObesityNCT07803185
Evaluation of Anhedonia and Emotional Eating in Individuals Using GLP-1 Receptor Agonists
An observational study of Obesity and Emotional Eating, run by TC Erciyes University at 1 site in Turkey (Türkiye).
Trial summary
This prospective observational study evaluates the longitudinal changes in anhedonia levels and emotional eating behaviors among adult individuals initiating glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight loss. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity, Emotional Eating, Anhedonia
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jun 2026to 31 Dec 2026
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients attending the Erciyes University Faculty of Medicine Endocrinology and Metabolism Outpatient Clinic who are newly prescribed GLP-1 receptor agonists for weight management.
Who may be able to join
- Age 18 years or older
- Newly initiated on GLP-1 receptor agonist treatment for weight reduction
- Willingness to participate in evaluations at baseline and at the 6-month follow-up
- Ability to read and understand Turkish and possess the cognitive capacity to answer questionnaire items
- Voluntary provision of written informed consent
Who cannot join
- Use of GLP-1 receptor agonists for indications other than weight loss
- Cognitive, neurological, or severe psychiatric conditions preventing completion of self-report questionnaires
- Substantial missing, inconsistent, or unverifiable questionnaire data compromising analysis integrity
- Non-participation or dropout at the 6-month follow-up evaluation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Erciyes University Medical Faculty Hospitals, Department of Endocrinology and Metabolism
Kayseri, Melikgazi, 38000
Hasan Durmuş, MD, Assoc. Prof., +90 544 370 6917, drhasandurmus@gmail.com
About this study
Official title: Longitudinal Evaluation of Anhedonia and Emotional Eating Behavior in Individuals Using Glucagon-Like Peptide-1 Receptor Agonists
This prospective observational study evaluates the longitudinal changes in anhedonia levels and emotional eating behaviors among adult individuals initiating glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight loss. Participants are assessed at baseline (treatment initiation) and after a 6-month follow-up period using standardized psychometric instruments.
Read the detailed description
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used in the management of obesity and type 2 diabetes by promoting satiety, delaying gastric emptying, and reducing appetite. Beyond peripheral metabolic regulation, GLP-1 receptors located in central reward circuitry suggest potential modulation of psychobiological processes, including reward processing, emotional eating, and anhedonia. However, longitudinal clinical data investigating the trajectory of anhedonia and emotional eating in patients using GLP-1 receptor agonists remain limited. This prospective, single-center observational cohort study is conducted at the Endocrinology and Metabolism Outpatient Clinic of Erciyes University. A total of 60 adult participants newly initiating GLP-1 receptor agonist therapy for weight management are enrolled.
- Data collection is performed in two main phases:Baseline Assessment: Demographic characteristics, baseline anhedonia levels via the Dimensional Anhedonia Rating Scale (DARS), and emotional eating patterns via the Emotional Eating Scale (EES / DYÖ) are collected prior to or at the start of therapy.
- 6-Month Follow-up Assessment: Participants are re-evaluated using the DARS and EES instruments. In addition, treatment adherence, current dosage, adverse events, and changes in appetite are documented.
- Conditions
- Obesity, Emotional Eating, Anhedonia
- Keywords
- GLP-1 Receptor Agonist, Glucagon-Like Peptide-1, Appetite Regulation, Reward System, Weight Loss
- Medical subject headings
- Obesity, Emotional Eating, Anhedonia, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| GLP-1 Receptor Agonist Group | Adult participants who have newly initiated GLP-1 receptor agonist treatment for weight reduction and are evaluated at baseline and at 6 months. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Dimensional Anhedonia Rating Scale (DARS) Score
The DARS is a 17-item self-report questionnaire assessing state anhedonia across four domains (hobbies, food/drink, social activities, and sensory experiences). Each item is scored on a 5-point Likert scale from 0 ("Not at all") to 4 ("Extremely"), yielding a total score between 0 and 68. Lower scores indicate more severe anhedonia.
Measured: Baseline and 6 months
Secondary outcomes (1)
Change in Emotional Eating Scale (EES) Score
The Turkish version of the Emotional Eating Scale (DYÖ) consists of 10 items assessing emotional eating across 3 subscales (inability to resist eating desire, food types, and feelings of guilt). Scored on a 4-point Likert scale from 0 ("Never") to 3 ("Always"), total scores range from 0 to 30. Higher scores reflect higher levels of emotional eating behavior.
Measured: Baseline and 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2026
- Study start1 Jun 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by TC Erciyes UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- TC Erciyes University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hasan Durmuş, TC Erciyes University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07803185
- Sponsor's protocol ID
- 2026/173
- Other IDs
- 2026/173
- Status last verified
- Aug 2026
- First submitted
- 31 Aug 2026
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Yapici-Eser H, Appadurai V, Eren CY, Yazici D, Chen CY, Ongur D, Pizzagalli DA, Werge T, Hall MH. Association between GLP-1 receptor gene polymorphisms with reward learning, anhedonia and depression diagnosis. Acta Neuropsychiatr. 2020 Aug;32(4):218-225. doi: 10.1017/neu.2020.14. Epub 2020 Mar 26.
PubMed 32213216Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am J Med. 2025 Jun;138(6):934-940. doi: 10.1016/j.amjmed.2025.01.021. Epub 2025 Jan 31.
PubMed 39892489
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Longitudinal Evaluation of Anhedonia and Emotional Eating Behavior in Individuals Using Glucagon-Like Peptide-1 Receptor Agonists
- ClinicalTrials.gov ID
- NCT07803185
- Acronym / sponsor ID
- 2026/173
- Conditions
- Obesity, Emotional Eating, Anhedonia
- Keywords
- GLP-1 Receptor Agonist, Glucagon-Like Peptide-1, Appetite Regulation, Reward System, Weight Loss
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- TC Erciyes UniversityUniversity, hospital or other
- Study start
- 1 Jun 2026 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 3 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective observational study evaluates the longitudinal changes in anhedonia levels and emotional eating behaviors among adult individuals initiating glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight loss. Participants are assessed at baseline (treatment initiation) and after a 6-month follow-up period using standardized psychometric instruments.
Detailed description
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used in the management of obesity and type 2 diabetes by promoting satiety, delaying gastric emptying, and reducing appetite. Beyond peripheral metabolic regulation, GLP-1 receptors located in central reward circuitry suggest potential modulation of psychobiological processes, including reward processing, emotional eating, and anhedonia. However, longitudinal clinical data investigating the trajectory of anhedonia and emotional eating in patients using GLP-1 receptor agonists remain limited. This prospective, single-center observational cohort study is conducted at the Endocrinology and Metabolism Outpatient Clinic of Erciyes University. A total of 60 adult participants newly initiating GLP-1 receptor agonist therapy for weight management are enrolled.
- Data collection is performed in two main phases:Baseline Assessment: Demographic characteristics, baseline anhedonia levels via the Dimensional Anhedonia Rating Scale (DARS), and emotional eating patterns via the Emotional Eating Scale (EES / DYÖ) are collected prior to or at the start of therapy.
- 6-Month Follow-up Assessment: Participants are re-evaluated using the DARS and EES instruments. In addition, treatment adherence, current dosage, adverse events, and changes in appetite are documented.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 6 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| GLP-1 Receptor Agonist Group | – | –Adult participants who have newly initiated GLP-1 receptor agonist treatment for weight reduction and are evaluated at baseline and at 6 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients attending the Erciyes University Faculty of Medicine Endocrinology and Metabolism Outpatient Clinic who are newly prescribed GLP-1 receptor agonists for weight management.
Key inclusion criteria (5 listed)
- Age 18 years or older
- Newly initiated on GLP-1 receptor agonist treatment for weight reduction
- Willingness to participate in evaluations at baseline and at the 6-month follow-up
- Ability to read and understand Turkish and possess the cognitive capacity to answer questionnaire items
- Voluntary provision of written informed consent
Key exclusion criteria (4 listed)
- Use of GLP-1 receptor agonists for indications other than weight loss
- Cognitive, neurological, or severe psychiatric conditions preventing completion of self-report questionnaires
- Substantial missing, inconsistent, or unverifiable questionnaire data compromising analysis integrity
- Non-participation or dropout at the 6-month follow-up evaluation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in Dimensional Anhedonia Rating Scale (DARS) Score
Time frame: Baseline and 6 months
The DARS is a 17-item self-report questionnaire assessing state anhedonia across four domains (hobbies, food/drink, social activities, and sensory experiences). Each item is scored on a 5-point Likert scale from 0 ("Not at all") to 4 ("Extremely"), yielding a total score between 0 and 68. Lower scores indicate more severe anhedonia.
1 secondary outcome
Change in Emotional Eating Scale (EES) Score
Time frame: Baseline and 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
- Background: PubMed 32213216Yapici-Eser H, Appadurai V, Eren CY, Yazici D, Chen CY, Ongur D, Pizzagalli DA, Werge T, Hall MH. Association between GLP-1 receptor gene polymorphisms with reward learning, anhedonia and depression diagnosis. Acta Neuropsychiatr. 2020 Aug;32(4):218-225. doi: 10.1017/neu.2020.14. Epub 2020 Mar 26.
- Background: PubMed 39892489Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am J Med. 2025 Jun;138(6):934-940. doi: 10.1016/j.amjmed.2025.01.021. Epub 2025 Jan 31.
- Individual participant dataSharing planned: No
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity and Emotional Eating, run by TC Erciyes University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hasan Durmuş, MD, Assoc. Prof. (+90 544 370 6917, asandurmus@erciyes.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Dimensional Anhedonia Rating Scale (DARS) Score (time frame: Baseline and 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07803185, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.